Key statistics
On Friday, Theriva Biologics Inc (TOVX:ASQ) closed at 0.20, 22.85% above the 52 week low of 0.1628 set on Feb 23, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.195 |
|---|---|
| High | 0.20 |
| Low | 0.184 |
| Bid | 0.1904 |
| Offer | 0.1959 |
| Previous close | 0.197 |
| Average volume | 32.19m |
|---|---|
| Shares outstanding | 35.69m |
| Free float | 34.95m |
| P/E (TTM) | -- |
| Market cap | 7.14m USD |
| EPS (TTM) | -5.53 USD |
Data delayed at least 15 minutes, as of Feb 27 2026 21:00 GMT.
More ▼
- Theriva™ Biologics concede la licencia de SYN-020 a Rasayana Therapeutics para numerosas indicaciones
- Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
- Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
- Theriva™ Biologics anuncia la próxima presentación de los datos del ensayo clínico de Fase 1 del VCN-01 para el retinoblastoma en el Congreso de la Academia de Oftalmología de Asia-Pacífico (APAO) de 2026
- Theriva™ Biologics anuncia el asesoramiento científico favorable de la Agencia Europea de Medicamentos (EMA) sobre el diseño de un ensayo de fase III de VCN-01 en el adenocarcinoma ductal pancreático (ACDP) metastásico
- Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del tercer trimestre de 2025
- Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results
- Theriva™ Biologics anuncia una operación de incentivo de warrants por un importe bruto de 4 millones de dólares
- Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds
More ▼
